Danielle Brill

Denali Therapeutics Inc (NASDAQ:DNLI) shares are moving lower in Thursday’s after-hours session after the company announced that its Phase 2 study of oditrasertib was discontinued. What Happened: After the market close on Thursday, Denali said strategic partner Sanofi SA (NASDAQ:SNY) informed...

Biogen Inc (NASDAQ: BIIB) has been in focus due to its treatment for early-stage Alzheimer’s disease. The launch of Leqembi, a treatment to slow the progression of Alzheimer's disease, is likely to begin gaining momentum in 2024, “with robust acceleration anticipated when the SC...

Shares of Biogen Inc (NASDAQ: BIIB) were flying on Wednesday, after the biopharma company said its experimental Alzheimer’s drug with Japanese partner Eisai showed promising results. RBC Capital Markets On Biogen Analyst Brian Abrahams maintained an Outperform rating, while raising the price...

FibroGen, Inc. (NASDAQ: FGEN) has a key catalyst Thursday when FDA's Cardiovascular and Renal Drugs Advisory Committee will issue its recommendation on the company's new drug application for roxadustat. The committee is scheduled to meet between 9:30 a.m. and 5:30 p.m. Roxadustat was ...

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) said late Monday it was notified by the Food and Drug Administration of deficiencies in its regulatory application to expand the label for pimavanserin, which goes by the brand name Nuplazid. The company is seeking approval for Nuplazid as a...

Keros Therapeutics Inc (NASDAQ: KROS), a clinical-stage biopharma focused on the development of treatments for rare hematologic and musculoskeletal disorders, went public in April.  With the IPO quiet period expiring, analysts are starting coverage of the stock — and adopting a bullish...

GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) opened higher by 8 percent Tuesday after posting positive results from its Phase 3 Epidiolex trial and second-quarter earnings beats. Here’s what analysts are saying. Epidiolex Sales GW Pharma closed out its first full quarter of Epidiolex sales...

The Food and Drug Administration assigned ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)’s Nuplazid a positive safety profile Thursday, sending shares soaring 27 percent. The run is just getting started, according to Piper Jaffray.  The Analyst  Piper Jaffray analyst Danielle Brill...

Acceleron Pharma Inc (NASDAQ: XLRN) has a rich pipeline that positions the stock for additional upside, according to Piper Jaffray. The Analyst Analyst Danielle Brill upgraded Acceleron from Neutral to Overweight and increased the price target from $52 to $75, suggesting roughly 45-...

Needham upgraded shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) from Hold to Buy, with a price target of $155. The price target, according to the firm, is based on 25 times its estimated earnings per share for 2022, discounted 20 percent annually. Analysts Alan Carr and Danielle...